Recent advances on nitric oxide in the upper airways

Current Medicinal Chemistry

Volumn 23, Issue 24, 2016, Pages 2736-2745

  Maniscalco, Mauro ^a,b   Bianco, Andrea ^c   Mazzarella, Gennaro ^c   Motta, Andrea ^d  

^a IRCCS   (Italy)

^b Hospital S Maria della Pieta Casoria   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CNR   (Italy)

Author keywords

Asthma; Humming; Inflammation; Nose; PCD; Polyposis; Sinusitis

Indexed keywords

NITRIC OXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE DONOR;

ALLERGIC RHINITIS; CILIARY DYSKINESIA; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; HUMAN; NOSE; PARANASAL SINUS; RESPIRATORY TRACT INFLAMMATION; REVIEW; SINUSITIS; UPPER RESPIRATORY TRACT; ANTAGONISTS AND INHIBITORS; ASTHMA; DRUG EFFECTS; KARTAGENER SYNDROME; MAXILLARY SINUS; METABOLISM; RESPIRATORY SYSTEM;

ASTHMA; HUMANS; KARTAGENER SYNDROME; MAXILLARY SINUS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; RESPIRATORY SYSTEM; SINUSITIS;

EID: 84989166027     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160627115335     Document Type: Review

References (104)

1. Furchgott, R. F.; Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288(5789), 373-376.
2. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA, 1987, 84(24), 9265-9269.
3. Palmer, R. M.; Ferrige, A. G.; Moncada, S. Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature, 1987, 327(6122), 524-526.
4. Moncada, S.; Palmer, R. M.; Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43(2), 109-142.
5. Coleman, J. W. Nitric oxide in immunity and inflammation. Int. Immunopharmacol., 2001, 1(8), 1397-1406.
6. Gustafsson, L. E.; Leone, A. M.; Persson, M. G.; Wiklund, N. P.; Moncada, S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun., 1991, 181(2), 852-857.
7. Alving, K.; Weitzberg, E.; Lundberg, J. M. Increased amount of nitric oxide in exhaled air of asthmatics. Eur. Respir. J., 1993, 6(9), 1368-1370.
8. Lundberg, J. O.; Weitzberg, E. Nasal nitric oxide in man. Thorax, 1999, 54(10), 947-952.
9. Lundberg, J. O.; Farkas-Szallasi, T.; Weitzberg, E.; Rinder, J.; Lidholm, J.; Anggaard, A.; Hokfelt, T.; Lundberg, J. M.; Alving, K. High nitric oxide production in human paranasal sinuses. Nat. Med., 1995, 1(4), 370-373.
10. Maniscalco, M.; Sofia, M.; Pelaia, G. Nitric oxide in upper airways inflammatory diseases. Inflamm. Res., 2007, 56(2), 58-69.
11. Kawamoto, H.; Takumida, M.; Takeno, S.; Watanabe, H.; Fukushima, N.; Yajin, K. Localization of nitric oxide synthase in human nasal mucosa with nasal allergy. Acta Otolaryngol. Suppl., 1998, 539, 65-70.
12. Kawamoto, H.; Takeno, S.; Yajin, K. Increased expression of inducible nitric oxide synthase in nasal epithelial cells in patients with allergic rhinitis. Laryngoscope, 1999, 109(12), 2015-2020.
13. Giannessi, F.; Fattori, B.; Ursino, F.; Giambelluca, M. A.; Soldani, P.; Scavuzzo, M. C.; Ruffoli, R. Ultrastructural and ultracytochemical study of the human nasal respiratory epithelium in vasomotor rhinitis. Acta Otolaryngol., 2003, 123(8), 943-949.
14. Lundberg, J. O.; Weitzberg, E.; Rinder, J.; Rudehill, A.; Jansson, O.; Wiklund, N. P.; Lundberg, J. M.; Alving, K. Calcium-independent and steroid-resistant nitric oxide synthase activity in human paranasal sinus mucosa. Eur. Respir. J., 1996, 9(7), 1344-1347.
15. Mancinelli, R. L.; McKay, C. P. Effects of nitric oxide and nitrogen dioxide on bacterial growth. Appl. Environ. Microbiol., 1983, 46(1), 198-202.
16. Chen, J. H.; Takeno, S.; Osada, R.; Ueda, T.; Yajin, K. Modulation of ciliary activity by tumor necrosis factoralpha in cultured sinus epithelial cells. Possible roles of nitric oxide. Hiroshima J. Med. Sci., 2000, 49(1), 49-55.
17. Lindberg, S.; Cervin, A.; Runer, T. Low levels of nasal nitric oxide (NO) correlate to impaired mucociliary function in the upper airways. Acta Otolaryngol., 1997, 117(5), 728-734.
18. Holden, W. E.; Wilkins, J. P.; Harris, M.; Milczuk, H. A.; Giraud, G. D. Temperature conditioning of nasal air: effects of vasoactive agents and involvement of nitric oxide. J. Appl. Physiol., 1999, 87(4), 1260-1265.
19. Silkoff, P. E.; Roth, Y.; McClean, P.; Cole, P.; Chapnik, J.; Zamel, N. Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis. Ann. Otol. Rhinol. Laryngol., 1999, 108(4), 368-372.
20. Maniscalco, M.; Sofia, M.; Faraone, S.; Carratu, L. The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. Allergy, 2000, 55(8), 757-761.
21. Gerlach, H.; Rossaint, R.; Pappert, D.; Knorr, M.; Falke, K. J. Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx. Lancet, 1994, 343(8896), 518-519.
22. Lundberg, J. O. Airborne nitric oxide: inflammatory marker and aerocrine messenger in man. Acta Physiol. Scand. Suppl., 1996, 633, 1-27.
23. Sanchez Crespo, A; Hallberg, J; Lundberg, JO; Lindahl, SG; Jacobsson, H; Weitzberg, E; Nyren, S Nasal nitric oxide and regulation of human pulmonary blood flow in the upright position. J. Appl. Physiol. (1985), 2010, 108(1), 181-188.
24. Lundberg, J. O.; Lundberg, J. M.; Settergren, G.; Alving, K.; Weitzberg, E. Nitric oxide, produced in the upper airways, may act in an 'aerocrine-fashion to enhance pulmonary oxygen uptake in humans. Acta Physiol. Scand., 1995, 155(4), 467-468.
25. Grisham, M. B.; Jourd-Heuil, D.; Wink, D. A. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am. J. Physiol., 1999, 276(2 Pt 1), G315-G321.
26. Ross, R.; Reske-Kunz, A. B. The role of NO in contact hypersensitivity. Int. Immunopharmacol., 2001, 1(8), 1469-1478.
27. Meurs, H.; Maarsingh, H.; Zaagsma, J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol. Sci., 2003, 24(9), 450-455.
28. Ricciardolo, F. L.; Zaagsma, J.; Meurs, H. The therapeutic potential of drugs targeting the arginase pathway in asthma. Expert Opin. Investig. Drugs, 2005, 14(10), 1221-1231.
29. Meurs, H.; McKay, S.; Maarsingh, H.; Hamer, M. A.; Macic, L.; Molendijk, N.; Zaagsma, J. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br. J. Pharmacol., 2002, 136(3), 391-398.
30. Zimmermann, N.; King, N. E.; Laporte, J.; Yang, M.; Mishra, A.; Pope, S. M.; Muntel, E. E.; Witte, D. P.; Pegg, A. A.; Foster, P. S.; Hamid, Q.; Rothenberg, M. E. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest., 2003, 111(12), 1863-1874.
31. Schuiling, M.; Meurs, H.; Zuidhof, A. B.; Venema, N.; Zaagsma, J. Dual action of iNOS-derived nitric oxide in allergen-induced airway hyperreactivity in conscious, unrestrained guinea pigs. Am. J. Respir. Crit. Care Med., 1998, 158(5 Pt 1), 1442-1449.
32. Sadeghi-Hashjin, G.; Folkerts, G.; Henricks, P. A.; Muijsers, R. B.; Nijkamp, F. P. Peroxynitrite in airway diseases. Clin. Exp. Allergy, 1998, 28(12), 1464-1473.
33. Takeno, S.; Osada, R.; Furukido, K.; Chen, J. H.; Yajin, K. Increased nitric oxide production in nasal epithelial cells from allergic patients-RT-PCR analysis and direct imaging by a fluorescence indicator: DAF-2 DA. Clin. Exp. Allergy, 2001, 31(6), 881-888.
34. Kang, B. H.; Chen, S. S.; Jou, L. S.; Weng, P. K.; Wang, H. W. Immunolocalization of inducible nitric oxide synthase and 3-nitrotyrosine in the nasal mucosa of patients with rhinitis. Eur. Arch. Otorhinolaryngol., 2000, 257(5), 242-246.
35. Maniscalco, M.; Ferrara, G.; Carratu, L.; Sofia, M. Nitric oxide attenuates platelet-activating factor induced nasal airway plasma extravasation in healthy subjects. Eur. J. Clin. Invest., 2002, 32(11), 858-861.
36. Colantonio, D.; Brouillette, L.; Parikh, A.; Scadding, G. K. Paradoxical low nasal nitric oxide in nasal polyposis. Clin. Exp. Allergy, 2002, 32(5), 698-701.
37. Parikh, A.; Scadding, G. K.; Gray, P.; Belvisi, M. G.; Mitchell, J. A. High levels of nitric oxide synthase activityare associated with nasal polyp tissue from aspirin-sensitive asthmatics. Acta Otolaryngol., 2002, 122(3), 302-305.
38. Ragab, S. M.; Lund, V. J.; Saleh, H. A.; Scadding, G. Nasal nitric oxide in objective evaluation of chronic rhinosinusitis therapy. Allergy, 2006, 61(6), 717-724.
39. Arnal, J. F.; Flores, P.; Rami, J.; Murris-Espin, M.; Bremont, F.; Pasto I Aguilla, M.; Serrano, E.; Didier, A. Nasal nitric oxide concentration in paranasal sinus inflammatory diseases. Eur. Respir. J., 1999, 13(2), 307-312.
40. Rouby, J. J. The nose, nitric oxide, and paranasal sinuses: The outpost of pulmonary antiinfectious defenses? Am. J. Respir. Crit. Care Med., 2003, 168(3), 265-266.
41. Baraldi, E.; Azzolin, N. M.; Carra, S.; Dario, C.; Marchesini, L.; Zacchello, F. Effect of topical steroids on nasal nitric oxide production in children with perennial allergic rhinitis: A pilot study. Respir. Med., 1998, 92(3), 558-561.
42. Wilson, A. M.; Dempsey, O. J.; Sims, E. J.; Lipworth, B. J. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol., 2000, 85(2), 111-114.
43. Lindberg, S.; Cervin, A.; Runer, T. Nitric oxide (NO) production in the upper airways is decreased in chronic sinusitis. Acta Otolaryngol., 1997, 117(1), 113-117.
44. Deja, M.; Busch, T.; Bachmann, S.; Riskowski, K.; Campean, V.; Wiedmann, B.; Schwabe, M.; Hell, B.; Pfeilschifter, J.; Falke, K. J.; Lewandowski, K. Reduced nitric oxide in sinus epithelium of patients with radiologic maxillary sinusitis and sepsis. Am. J. Respir. Crit. Care Med., 2003, 168(3), 281-286.
45. Baraldi, E.; Azzolin, N. M.; Biban, P.; Zacchello, F. Effect of antibiotic therapy on nasal nitric oxide concentration in children with acute sinusitis. Am. J. Respir. Crit. Care Med., 1997, 155(5), 1680-1683.
46. Bush, A. Primary ciliary dyskinesia. Acta Otorhinolaryngol. Belg., 2000, 54(3), 317-324.
47. Grasemann, H.; Gartig, S. S.; Wiesemann, H. G.; Teschler, H.; Konietzko, N.; Ratjen, F. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur. Respir. J., 1999, 13(1), 114-118.
48. Karadag, B.; James, A. J.; Gultekin, E.; Wilson, N. M.; Bush, A. Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia. Eur. Respir. J., 1999, 13(6), 1402-1405.
49. Wodehouse, T.; Kharitonov, S. A.; Mackay, I. S.; Barnes, P. J.; Wilson, R.; Cole, P. J. Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. Eur. Respir. J., 2003, 21(1), 43-47.
50. Horvath, I.; Loukides, S.; Wodehouse, T.; Csiszer, E.; Cole, P. J.; Kharitonov, S. A.; Barnes, P. J. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax, 2003, 58(1), 68-72.
51. Csoma, Z.; Bush, A.; Wilson, N. M.; Donnelly, L.; Balint, B.; Barnes, P. J.; Kharitonov, S. A. Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. Chest, 2003, 124(2), 633-638.
52. Narang, I.; Ersu, R.; Wilson, N. M.; Bush, A. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. Thorax, 2002, 57(7), 586-589.
53. Noone, P. G.; Leigh, M. W.; Sannuti, A.; Minnix, S. L.; Carson, J. L.; Hazucha, M.; Zariwala, M. A.; Knowles, M. R. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am. J. Respir. Crit. Care Med., 2004, 169(4), 459-467.
54. Corbelli, R.; Bringolf-Isler, B.; Amacher, A.; Sasse, B.; Spycher, M.; Hammer, J. Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia. Chest, 2004, 126(4), 1054-1059.
55. Baraldi, E.; Pasquale, M. F.; Cangiotti, A. M.; Zanconato, S.; Zacchello, F. Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia. Eur. Respir. J., 2004, 24(5), 881-883.
56. Mahut, B.; Escudier, E.; de Blic, J.; Zerah-Lancner, F.; Coste, A.; Harf, A.; Delclaux, C. Impairment of nitric oxide output of conducting airways in primary ciliary dyskinesia. Pediatr. Pulmonol., 2006, 41(2), 158-163.
57. Walker, W. T.; Jackson, C. L.; Lackie, P. M.; Hogg, C.; Lucas, J. S. Nitric oxide in primary ciliary dyskinesia. Eur. Respir. J., 2012, 40(4), 1024-1032.
58. Maniscalco, M.; Sofia, M. Nasal nitric oxide in experimental rhinovirus infection. J. Allergy Clin. Immunol., 2005, 115(1), 207.
59. Smith, C. M.; Fadaee-Shohada, M. J.; Sawhney, R.; Baker, N.; Williams, G.; Hirst, R. A.; Andrew, P. W.; O-Callaghan, C. Ciliated cultures from patients with primary ciliary dyskinesia do not produce nitric oxide or inducible nitric oxide synthase during early infection. Chest, 2013, 144(5), 1671-1676.
60. Santamaria, F.; De Stefano, S.; Montella, S.; Barbarano, F.; Iacotucci, P.; Ciccarelli, R.; Sofia, M.; Maniscalco, M. Nasal nitric oxide assessment in primary ciliary dyskinesia using aspiration, exhalation, and humming. Med. Sci. Monit., 2008, 14(2), CR80-CR85.
61. Pifferi, M.; Bush, A.; Caramella, D.; Di Cicco, M.; Zangani, M.; Chinellato, I.; Macchia, P.; Boner, A. L. Agenesis of paranasal sinuses and nasal nitric oxide in primary ciliary dyskinesia. Eur. Respir. J., 2011, 37(3), 566-571.
62. Grasemann, H.; Schwiertz, R.; Matthiesen, S.; Racke, K.; Ratjen, F. Increased arginase activity in cystic fibrosis airways. Am. J. Respir. Crit. Care Med., 2005, 172(12), 1523-1528.
63. Knowles, M.; Gatzy, J.; Boucher, R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N. Engl. J. Med., 1981, 305(25), 1489-1495.
64. Kulczycki, L. L.; Kostuch, M.; Bellanti, J. A. A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype-phenotype manifestations. Am. J. Med. Genet. A., 2003, 116A(3), 262-267.
65. Zheng, S.; Xu, W.; Bose, S.; Banerjee, A. K.; Haque, S. J.; Erzurum, S. C. Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol., 2004, 287(2), L374-L381.
66. Kelley, T. J.; Drumm, M. L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J. Clin. Invest., 1998, 102(6), 1200-1207.
67. Dotsch, J.; Puls, J.; Klimek, T.; Rascher, W. Reduction of neuronal and inducible nitric oxide synthase gene expression in patients with cystic fibrosis. Eur. Arch. Otorhinolaryngol., 2002, 259(4), 222-226.
68. Grasemann, H.; Ratjen, F. Cystic fibrosis lung disease: The role of nitric oxide. Pediatr. Pulmonol., 1999, 28(6), 442-448.
69. Grasemann, H.; Storm van-s Gravesande, K.; Gartig, S.; Kirsch, M.; Buscher, R.; Drazen, J. M.; Ratjen, F. Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal NO synthase (NOS1) gene polymorphism. Nitric Oxide, 2002, 6(2), 236-241.
70. Grasemann, H.; Ratjen, F. Nitric oxide and L-arginine deficiency in cystic fibrosis. Curr. Pharm. Des., 2012, 18(5), 726-736.
71. de Winter-de Groot, K. M.; van Haren Noman, S.; Speleman, L.; Schilder, A. G.; van der Ent, C. K. Nasal nitric oxide levels and nasal polyposis in children and adolescents with cystic fibrosis. JAMA Otolaryngol. Head Neck Surg., 2013, 139(9), 931-936.
72. Balfour-Lynn, I. M.; Laverty, A.; Dinwiddie, R. Reduced upper airway nitric oxide in cystic fibrosis. Arch. Dis. Child., 1996, 75(4), 319-322.
73. Cristescu, S. M.; Mandon, J.; Harren, F. J.; Merilainen, P.; Hogman, M. Methods of NO detection in exhaled breath. J. Breath Res., 2013, 7(1), 017104.
74. American Thoracic Society; European Respiratory Society. Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am. J. Respir. Crit. Care Med., 2005, 171(8), 912-930.
75. Dweik, R. A.; Boggs, P. B.; Erzurum, S. C.; Irvin, C. G.; Leigh, M. W.; Lundberg, J. O.; Olin, A. C.; Plummer, A. L.; Taylor, D. R. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med., 2011, 184(5), 602-615.
76. Collins, S. A.; Gove, K.; Walker, W.; Lucas, J. S. Nasal nitric oxide screening for primary ciliary dyskinesia: systematic review and meta-analysis. Eur. Respir. J., 2014, 44(6), 1589-1599.
77. Knowles, M. R.; Daniels, L. A.; Davis, S. D.; Zariwala, M. A.; Leigh, M. W. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am. J. Respir. Crit. Care Med., 2013, 188(8), 913-922.
78. Fokkens, W. J.; Lund, V. J.; Mullol, J.; Bachert, C.; Alobid, I.; Baroody, F.; Cohen, N.; Cervin, A.; Douglas, R.; Gevaert, P.; Georgalas, C.; Goossens, H.; Harvey, R.; Hellings, P.; Hopkins, C.; Jones, N.; Joos, G.; Kalogjera, L.; Kern, B.; Kowalski, M.; Price, D.; Riechelmann, H.; Schlosser, R.; Senior, B.; Thomas, M.; Toskala, E.; Voegels, R.; Wang, Y.; Wormald, P. J. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50(1), 1-12.
79. Leigh, M. W.; Hazucha, M. J.; Chawla, K. K.; Baker, B. R.; Shapiro, A. J.; Brown, D. E.; Lavange, L. M.; Horton, B. J.; Qaqish, B.; Carson, J. L.; Davis, S. D.; Dell, S. D.; Ferkol, T. W.; Atkinson, J. J.; Olivier, K. N.; Sagel, S. D.; Rosenfeld, M.; Milla, C.; Lee, H. S.; Krischer, J.; Zariwala, M. A.; Knowles, M. R. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann. Am. Thorac. Soc., 2013, 10(6), 574-581.
80. Collins, S. A.; Behan, L.; Harris, A.; Gove, K.; Lucas, J. S. The dangers of widespread nitric oxide screening for primary ciliary dyskinesia. Thorax, 2016, 71(6), 560-561.
81. Jackson, C. L.; Behan, L.; Collins, S. A.; Goggin, P. M.; Adam, E. C.; Coles, J. L.; Evans, H. J.; Harris, A.; Lackie, P.; Packham, S.; Page, A.; Thompson, J.; Walker, W. T.; Kuehni, C.; Lucas, J. S. Accuracy of diagnostic testing in primary ciliary dyskinesia. Eur. Respir. J., 2016, 47(3), 837-848.
82. Marthin, J. K.; Nielsen, K. G. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. Eur. Respir. J., 2011, 37(3), 559-565.
83. Thomas, S. R.; Kharitonov, S. A.; Scott, S. F.; Hodson, M. E.; Barnes, P. J. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest, 2000, 117(4), 1085-1089.
84. Manna, A.; Montella, S.; Maniscalco, M.; Maglione, M.; Santamaria, F. Clinical application of nasal nitric oxide measurement in pediatric airway diseases. Pediatr. Pulmonol., 2015, 50(1), 85-99.
85. Scadding, G.; Scadding, G. K. Update on the use of nitric oxide as a noninvasive measure of airways inflammation. Rhinology, 2009, 47(2), 115-120.
86. Phillips, P. S.; Sacks, R.; Marcells, G. N.; Cohen, N. A.; Harvey, R. J. Nasal nitric oxide and sinonasal disease: A systematic review of published evidence. Otolaryngol. Head Neck Surg., 2011, 144(2), 159-169.
87. Maniscalco, M.; Pelaia, G.; Sofia, M. Exhaled nasal nitric oxide during humming: potential clinical tool in sinonasal disease? Biomarkers Med., 2013, 7(2), 261-266.
88. Weitzberg, E.; Lundberg, J. O. Humming greatly increases nasal nitric oxide. Am. J. Respir. Crit. Care Med., 2002, 166(2), 144-145.
89. Maniscalco, M.; Weitzberg, E.; Sundberg, J.; Sofia, M.; Lundberg, J. O. Assessment of nasal and sinus nitric oxide output using single-breath humming exhalations. Eur. Respir. J., 2003, 22(2), 323-329.
90. Lundberg, J. O.; Maniscalco, M.; Sofia, M.; Lundblad, L.; Weitzberg, E. Humming, nitric oxide, and paranasal sinus obstruction. JAMA, 2003, 289(3), 302-303.
91. Maniscalco, M.; Sofia, M.; Weitzberg, E.; De Laurentiis, G.; Stanziola, A.; Rossillo, V.; Lundberg, J. O. Humminginduced release of nasal nitric oxide for assessment of sinus obstruction in allergic rhinitis: pilot study. Eur. J. Clin. Invest., 2004, 34(8), 555-560.
92. Shusterman, D. J.; Weaver, E. M.; Goldberg, A. N.; Schick, S. F.; Wong, H. H.; Balmes, J. R. Pilot evaluation of the nasal nitric oxide response to humming as an index of osteomeatal patency. Am. J. Rhinol. Allergy, 2012, 26(2), 123-126.
93. Barnes, M. L.; Menzies, D.; Fardon, T. C.; Burns, P.; Wilson, A. M.; Lipworth, B. J. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy, 2007, 62(1), 73-80.
94. Kharitonov, S. A.; Rajakulasingam, K.; O-Connor, B.; Durham, S. R.; Barnes, P. J. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J. Allergy Clin. Immunol., 1997, 99(1 Pt 1), 58-64.
95. Profita, M.; Riccobono, L.; Bonanno, A.; Chanez, P.; Gagliardo, R.; Montalbano, A. M.; Albano, G. D.; Liotta, G.; Gjomarkaj, M.; La Grutta, S. Effect of nebulized beclomethasone on airway inflammation and clinical status of children with allergic asthma and rhinitis: A randomized, double-blind, placebo-controlled study. Int. Arch. Allergy Immunol., 2013, 161(1), 53-64.
96. Pedroletti, C.; Lundahl, J.; Alving, K.; Hedlin, G. Effect of nasal steroid treatment on airway inflammation determined by exhaled nitric oxide in allergic schoolchildren with perennial rhinitis and asthma. Pediatr. Allergy Immunol., 2008, 19(3), 219-226.
97. Michl, R. K.; Hentschel, J.; Fischer, C.; Beck, J. F.; Mainz, J. G. Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers. PLoS One, 2013, 8(11), e79141.
98. Wilson, A. M.; Dempsey, O. J.; Sims, E. J.; Lipworth, B. J. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin. Exp. Allergy, 2001, 31(4), 616-624.
99. Barnes, M. L.; Ward, J. H.; Fardon, T. C.; Lipworth, B. J. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin. Exp. Allergy, 2006, 36(5), 676-684.
100. Marcucci, F.; Sensi, L. G.; Abate, P.; Allocca, G.; Ugolini, E.; Di Cara, G.; Incorvaia, C. Anti-inflammatory activity and clinical efficacy of a 3-month levocetirizine therapy inmite-allergic children. Inflamm. Allergy Drug Targets, 2011, 10(1), 32-38.
101. Runer, T.; Cervin, A.; Lindberg, S.; Uddman, R. Nitric oxide is a regulator of mucociliary activity in the upper respiratory tract. Otolaryngol. Head Neck Surg., 1998, 119(3), 278-287.
102. Runer, T.; Lindberg, S. Effects of nitric oxide on blood flow and mucociliary activity in the human nose. Ann. Otol. Rhinol. Laryngol., 1998, 107(1), 40-46.
103. Lundberg, J. O. Acute purulent sinusitis triggered by topical nasal nitric oxide synthase inhibition. Am. J. Respir. Crit. Care Med., 2005, 172(4), 512-513.
104. Balijepalli, A. S.; Comstock, A. T.; Wang, X.; Jensen, G. C.; Hershenson, M. B.; Zacharek, M. A.; Sajjan, U. S.; Meyerhoff, M. E. Enhancement of Inducible Nitric Oxide Synthase Activity by Low Molecular Weight Peptides Derived from Protamine: A Potential Therapy for Chronic Rhinosinusitis. Mol. Pharm., 2015, 12(7), 2396-2405.